Literature DB >> 15317464

High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor.

Ossama El-Kabbani1, Connie Darmanin, Mitsuru Oka, Clemens Schulze-Briese, Takashi Tomizaki, Isabelle Hazemann, Andre Mitschler, Alberto Podjarny.   

Abstract

Structure determinations of human aldose reductase holoenzyme in complex with the 2S4R-,2R4S- and 2R4R-isomers of the potent inhibitor Fidarestat ((2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamide) were carried out in order to elucidate the binding modes responsible for the differences in their inhibitory potencies. In the complex structure with the 2R4S-isomer the cyclic imide moiety formed hydrogen bonds with the side-chains of Trp111, Tyr48 and His110. In the attempt to determine the complex structure with the least potent 2R4R-isomer this ligand was not observed, and instead, the active site was simultaneously occupied by two citrate molecules (occupancies of 60% and 40%). In the case of 2S4R, the active site was occupied by a citrate molecule which anchors the 2S4R-isomer from its carbamoyl group. The structures of the complexes suggest that the differences in the interactions between the cyclic imide rings and carbamoyl groups of the compounds with residues His110, Trp111, Trp219 and Cys298 account for differences in their inhibitory potencies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15317464     DOI: 10.1021/jm0497794

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  The molecular structure of Rv2074, a probable pyridoxine 5'-phosphate oxidase from Mycobacterium tuberculosis, at 1.6 angstroms resolution.

Authors:  Bichitra K Biswal; Karolyn Au; Maia M Cherney; Craig Garen; Michael N G James
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-07-24

2.  Path-integral method for predicting relative binding affinities of protein-ligand complexes.

Authors:  Chandrika Mulakala; Yiannis N Kaznessis
Journal:  J Am Chem Soc       Date:  2009-04-01       Impact factor: 15.419

3.  Structure based comprehensive modelling, spatial fingerprints mapping and ADME screening of curcumin analogues as novel ALR2 inhibitors.

Authors:  Sant Kumar Verma; Suresh Thareja
Journal:  PLoS One       Date:  2017-04-11       Impact factor: 3.240

4.  Development, Molecular Docking, and In Silico ADME Evaluation of Selective ALR2 Inhibitors for the Treatment of Diabetic Complications via Suppression of the Polyol Pathway.

Authors:  Aqeel Imran; Muhammad Tariq Shehzad; Syed Jawad Ali Shah; Mark Laws; Taha Al-Adhami; Khondaker Miraz Rahman; Imtiaz Ali Khan; Zahid Shafiq; Jamshed Iqbal
Journal:  ACS Omega       Date:  2022-07-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.